Albany, NY -- (SBWIRE) -- 01/10/2018 -- Immunoassay is a bioanalytical method employed to determine or quantify the concentration of specific biomolecules in blood or other body fluids, which helps diagnose several types of diseases. Immunoassay methods are widely used in hospitals and diagnostic laboratories for diagnosis of diseases; in pharmaceutical and biotechnology industries to evaluate the therapeutic drug efficacy against several types of diseases; and in drug discovery and development studies. Immunoassays measure the concentration of antigen–antibody complexes and detect them through indicator reactions. Several immunoassay methods are available, for example, radioimmunoassay (RIA), enzyme immunoassay (EIA), fluoroimmunoassay (FIA), liposome immunoassay (LIA), and chemiluminescence immunoassay (CLIA).
Chemiluminescence immunoassay (CLIA) uses a chemiluminescent substance as a label. Chemiluminescent molecules produce the electromagnetic radiation in the form of light when these are excited by the energy released during chemical reactions. The CLIA method offers several advantages over other methods such as high performance levels, low detection limits, higher specificity, high signal intensity, and good precision. Also, the CLIA method offers a wide dynamic range and a linear relationship between the luminous intensity and concentration of measured substance.
Request Brochure of The Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31517
High performance, low detection limits, and wide usage of the chemiluminescent immunoassay method have led to increasing attention toward the method and its rising adoption by end-users. The growing number of applications of the CLIA method such as endocrinology, infectious disease testing, oncology, cardiology, and drug discovery and development is projected to be the key driving factor for the CLIA analyzers market during the forecast period. The increase in geriatric population requiring several pathological tests and rise in the incidence of infectious diseases and other chronic as well as acute diseases worldwide are likely to boost the demand for CLIA analyzers in the near future. A trend of laboratory automation is being observed in developed and developing countries, owing to increasing laboratory workflow, higher efficiency, and high throughput outcomes. Also, shortage of skilled professionals in most of the developed countries is generating the demand for laboratory automation. In addition, rapidly risen approvals for new drugs and drug discovery in the last decade, increased R&D budgets, and emergence of newer diseases augment the CLIA analyzers market. However, high cost, limited antigen detection, and closed analytical system of CLIA analyzer equipment are projected to restrain the market during the forecast period.
The global chemiluminescence immunoassay analyzers market can be broadly segmented based on end-user and geography. End-users of chemiluminescence immunoassay (CLIA) analyzers include pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, R&D laboratories, and academic & research institutes. The hospitals & diagnostic laboratories segment accounted for a major market share in 2016 and is likely to expand at the maximum CAGR from 2017 to 2025. This segment is projected to gain market share by the end of 2025, owing to the increasing number of hospitals and diagnostic laboratories, growing burden of infectious diseases in developing countries, and rising laboratory workflow.
Based on geography, the global chemiluminescence immunoassay (CLIA) analyzers market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2016 and is likely to lose market share to Asia Pacific and Europe by 2025. Well-established health care infrastructure, high R&D budgets, and growing biopharmaceutical industry in the region promoted growth of the CLIA analyzers market in North America in 2016. The market in Europe is anticipated to register the maximum growth rate during the forecast period, owing to developing health care facilities, growing burden of infectious diseases, and rising inclination toward laboratory automation in hospitals and diagnostic centers in the region. The market in Asia Pacific is projected to witness moderate growth during the forecast period and is likely to gain market share by 2025.
Request Discount @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=31517
Global companies such as Abbott Laboratories, Roche Diagnostics Corporation, and Siemens Healthcare Diagnostics accounted for key shares in the global chemiluminescent immunoassay analyzers market in 2016. Other players operating in this market are Beckman Coulter, Inc., Shenzhen Mindray Bio-Medical Electronics Co., AccuBioTech Co., Ltd., Maccura Biotechnology Co., Ltd., Trivitron Healthcare, AVIOQ, INC., Inova Diagnostics, bioMérieux, Inc., and SuZhou Hybiome Biomedical Engineering Co. Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Report Details @ https://www.transparencymarketresearch.com/chemiluminescence-immunoassay-analyzers-market.